Glenmark Pharmaceuticals has successfully closed the pricing of its debut $200 million 5-year non-call 3 year senior unsecured notes offering at 4.5% per annum, due 2021 (the 2016 Notes). The notes issuance follows a series of fixed income investor meetings in Asia and Europe, and was priced following strong demand aggregating $1.7 billion from a wide spectrum of institutional investors across Asia and Europe.
The bonds were oversubscribed 8 times and the notes have been rated BB and BB by S&P and Fitch respectively. The proceeds from the issuance and sale of the Notes will be used for investment in Glenmark’s wholly owned subsidiaries abroad, and will subsequently be applied to repay existing debt at the subsidiary level.
Citi and HSBC acted as Joint Global Coordinators and ANZ, Barclays and DB5 Bank acted as Joint Bookrunners and Joint Lead Managers to the offering.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1672.80 |
| Dr. Reddys Lab | 1238.00 |
| Cipla | 1238.25 |
| Zydus Lifesciences | 942.95 |
| Lupin | 2333.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: